Ebina, Japan

Yukari Hoshina

USPTO Granted Patents = 2 

 

Average Co-Inventor Count = 5.5

ph-index = 1


Company Filing History:


Years Active: 2010-2011

Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: Yukari Hoshina: Innovator in Pharmaceutical Composition

Introduction

Yukari Hoshina is a prominent inventor based in Ebina, Japan. She has made significant contributions to the field of pharmaceuticals, particularly in the development of therapeutic agents for various diseases. With a total of 2 patents, her work focuses on innovative solutions for allergic and inflammatory conditions.

Latest Patents

Hoshina's latest patents include a pharmaceutical composition for the prophylaxis or treatment of allergic ophthalmic diseases and allergic nasal diseases. This composition comprises a tricyclic triazolobenzazepine derivative, specifically 7,8-dimethoxy-4(5H),10-dioxo-1H-1,2,3-triazolo[4,5-c][1]benzazepine. The invention is notable for its minimal side effects and strong therapeutic effects, particularly in cases resistant to conventional treatments. Another significant patent relates to a method for maintaining remission or treating inflammatory bowel diseases. This method utilizes a therapeutically effective amount of the same triazolobenzazepine derivative, demonstrating effectiveness even in severe cases.

Career Highlights

Yukari Hoshina is currently associated with Meiji Seika Kaisha, Ltd., where she continues to advance her research and development efforts. Her work has garnered attention for its potential to improve patient outcomes in the treatment of allergic and inflammatory conditions.

Collaborations

Hoshina collaborates with esteemed colleagues, including Takashi Shishikura and Mitsuhiro Uchida, to further enhance her research initiatives and drive innovation in the pharmaceutical industry.

Conclusion

Yukari Hoshina's contributions to pharmaceutical innovations highlight her role as a leading inventor in her field. Her patents reflect a commitment to developing effective treatments with fewer side effects, ultimately benefiting patients worldwide.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…